Commentary & Deal Flow

Convatec Group plc (Ticker: CTECLN), a leading global medical products and technologies company, rated Baa3 (stable), BBB- (positive), BBB (stable) by Moody’s, S&P and Fitch, has mandated BofA Securities, HSBC, J.P. Morgan and NatWest to arrange a series of fixed income investor calls commencing 30 September 2025. HSBC will be co-ordinating logistics. A Deal Roadshow presentation with voiceover will be made available. A USD-denominated benchmark 144A/RegS 10-year senior unsecured fixed rate offering may follow, subject to market conditions. The notes will be issued by 180 Medical, Inc. and guaranteed by Convatec Group plc, Convatec Inc. and Convatec Finance Holdings Limited.

Convatec will be represented by:

Fiona Ryder, Interim Chief Financial Officer,

Daniel Sykes, Head of Treasury

David Phillips, VP, Head of Investor Relations

About Convatec:

Convatec is an innovative global medical products and technologies company, focused on solutions for the management of chronic conditions. The company has leading positions in Advanced Wound Care, Ostomy Care, Continence Care and Infusion Care. It provides products and services in approximately 90 countries and has more than 10,000 employees. The Group’s solutions provide a range of clinical and economic benefits, including infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue, to supporting debilitating conditions, improved patient outcomes and reduced care costs.